The Open Diabetes Journal

2009, 2 : 60-61
Published online 2009 August 31. DOI: 10.2174/1876524600902010060
Publisher ID: TODIAJ-2-60

Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes

Sachiko Honjo , Hiroki Ikeda , Yukiko Kawasaki , Yoshiharu Wada , Yoshiyuki Hamamoto , Tomohisa Aoyama , Tetsuya Kimura , Kazuhiro Nomura and Hiroyuki Koshiyama
Center for Diabetes & Endocrinology, Medical Institute Kitano Hospital, 2-4-20 Ohgi-machi, Kitaku Osaka, 530-8480, Japan.

ABSTRACT

We investigated the efficacy and safety of miglitol, a new alpha-glucosidase inhibitor, by switching from voglibose in Japanese patients with type 2 diabetes. Subjects included those who had previously been administered with voglibose (n=90, 0.6mg/day). After voglibose was changed into miglitol (150mg/day), HbA1C level, body weight and abdominal symptoms were evaluated six months later. HbA1C level was significantly decreased from 7.8±1.2 to 7.3±1.0% (P<0.01). Body weight showed a small but significant decrease after 6 months (62.5±11.0 to 62.1±12.3kg, P<0.01). There was no significant difference between frequencies of side effects before and after switching from voglibose to miglitol. This study suggests the efficacy and safety of miglitol to improve glycemic control in Japanese patients with type 2 diabetes, who had previously been treated with voglibose.